论文部分内容阅读
最近加拿大卫生部门首次批准了一类可用于流感治疗的新药,该类新药可使准确诊断传染的重要性有所增加。这种吸入剂Zanamivir(Relenga)与口服药物Osteltamivir(Tamiful)都必须在开始出现症状的48小时内给药,这意味着要求病人必须能够将流感与普通感冒的症状区别开来。预计Osteltamivir将在几个月内获准使用。据Manitoba大学的药物学教授Tred
For the first time, Canada’s health authorities recently approved a new class of drugs that can be used in flu therapies that could make it more important to accurately diagnose an infection. Both the inhalant Zanamivir (Relenga) and the oral drug Osteltamivir (Tamiful) must be administered within 48 hours of onset of symptoms, which means that the patient is required to be able to distinguish the flu from the symptoms of the common cold. Osteltamivir is expected to be approved within a few months. According to Tred, a professor of pharmacology at Manitoba University